These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17872364)

  • 21. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 22. Allergic and nonallergic delayed infusion reactions during natalizumab therapy.
    Hellwig K; Schimrigk S; Fischer M; Haghikia A; Müller T; Chan A; Gold R
    Arch Neurol; 2008 May; 65(5):656-8. PubMed ID: 18474743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
    Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis.
    Santos AC; Narayanan S; de Stefano N; Tartaglia MC; Francis SJ; Arnaoutelis R; Caramanos Z; Antel JP; Pike GB; Arnold DL
    J Neurol; 2002 Jun; 249(6):662-8. PubMed ID: 12111296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
    N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 'Time is brain' also in multiple sclerosis.
    Freedman MS
    Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
    N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnosis of MS: white spots and red flags.
    Ratchford JN; Calabresi PA
    Neurology; 2008 Mar; 70(13 Pt 2):1071-2. PubMed ID: 18362269
    [No Abstract]   [Full Text] [Related]  

  • 29. The pathologic substrate of magnetic resonance alterations in multiple sclerosis.
    Lassmann H
    Neuroimaging Clin N Am; 2008 Nov; 18(4):563-76, ix. PubMed ID: 19068402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica.
    Cabrera-Gómez JA; Quevedo-Sotolongo L; González-Quevedo A; Lima S; Real-González Y; Cristófol-Corominas M; Romero-García K; Ugarte-Sánchez C; Jordán-González J; de la Nuez JE; Lahera JG; Tellez R; Pedroso-Ibañez I; Roca RR; Cabrera-Núñez AY
    Mult Scler; 2007 Mar; 13(2):186-92. PubMed ID: 17439883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
    J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natalizumab in the treatment of pediatric multiple sclerosis.
    Talab R; Talabova M; Klzo L
    Neuro Endocrinol Lett; 2012; 33(6):579-89. PubMed ID: 23160229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.
    Moraal B; van den Elskamp IJ; Knol DL; Uitdehaag BM; Geurts JJ; Vrenken H; Pouwels PJ; van Schijndel RA; Meier DS; Guttmann CR; Barkhof F
    Ann Neurol; 2010 May; 67(5):667-75. PubMed ID: 20437564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?
    Lenhard T; Biller A; Mueller W; Metz I; Schönberger J; Wildemann B
    Neurology; 2010 Aug; 75(9):831-3. PubMed ID: 20805529
    [No Abstract]   [Full Text] [Related]  

  • 36. A case of MS presenting with SUNCT status.
    Bogorad I; Blum S; Green M
    Headache; 2010 Jan; 50(1):141-3. PubMed ID: 19751367
    [No Abstract]   [Full Text] [Related]  

  • 37. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
    Balcer LJ; Galetta SL; Calabresi PA; Confavreux C; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA
    Neurology; 2007 Apr; 68(16):1299-304. PubMed ID: 17438220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis.
    van den Elskamp IJ; Knol DL; Vrenken H; Karas G; Meijerman A; Filippi M; Kappos L; Fazekas F; Wagner K; Pohl C; Sandbrink R; Polman CH; Uitdehaag BM; Barkhof F
    Mult Scler; 2010 Jun; 16(6):660-9. PubMed ID: 20350960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.